The clinical observation of Zheng Qing Fen Tong Ning in treating herpetic neuralgia

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17012328

Enrollment

Unknown

Registered

2017-08-10

Start date

2017-09-01

Completion date

Unknown

Last updated

2017-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

herpes zoster neuralgia

Interventions

Control group A:Pregabalin

Control group B:gabapentin

Experimental group C:Pregabalin Capsules and Zhengqingfengtongning sustained release patches

Experimental group C:Gabapentin capsules and Zhengqingfengtongning sustained release patches

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Diagnosis and inclusion criteria met the International Association for pain research (IASP) diagnostic criteria for herpes zoster neuralgia. Over 60 years of age, visual analogue scale (VAS) more than 5 points, nausea and vomiting, dizziness, constipation, urinary retention and analgesic drug screening period before 2 weeks of taking other effects on central and peripheral.

Exclusion criteria

Exclusion criteria: No medical history and symptoms of herpes zoster, the diagnosis is not clear pain disease, had a history of asthma and allergy of sinomenine, organic disease is an important organ of serious heart, lung, liver, kidney, coagulation dysfunction, cognitive impairment.

Design outcomes

Primary

Measure	Time frame
the pain visual analogue scale (VAS);ID Pain scales;SF36 quality of life assessment form;	—

Countries

China

Contacts

Public ContactDaying Zhang

The First Affiliated Hospital of Nanchang University

zhangdayingpc2@126.com+86 13507913595

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026